David Hal­lal's El­e­vate­Bio launch­es new com­pa­ny to 'dis­rup­t' off-the-shelf cell ther­a­py, but pro­vides few oth­er de­tails

David Hal­lal’s El­e­vate­Bio is launch­ing a new com­pa­ny Thurs­day as it looks to con­tin­ue mak­ing its mark in the cell and gene ther­a­py spaces. But Hal­lal is al­so keep­ing his cards close to the vest, pre­fer­ring to toe the line be­tween bom­bast and mys­tique rather than go­ing all-in in one di­rec­tion.

The new com­pa­ny comes out of a part­ner­ship with Boston Chil­dren’s Hos­pi­tal and re­search from George Da­ley, the dean of Har­vard Med­ical School. The tri­umvi­rate claims to have found a way to de­sign bet­ter off-the-shelf cell ther­a­pies us­ing new meth­ods dis­cov­ered in Da­ley’s Boston Chil­dren’s Hos­pi­tal lab (Har­vard is not in­volved in the col­lab­o­ra­tion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER